Your browser doesn't support javascript.
loading
Evaluation of epicardial adipose tissue in familial partial lipodystrophy.
Godoy-Matos, Amélio Fernando; Valério, Cynthia M; Bragança, Juliana Bonadiman E; Oliveira, Ricardo de Andrade; Zagury, Roberto Luis; Lustosa, Rodolfo de Paula; Camargo, Gabriel Cordeiro; Nascimento, César Augusto da Silva; Moreira, Rodrigo O.
Afiliação
  • Godoy-Matos AF; Metabolism Unit, State Institute of Diabetes and Endocrinology, IEDE, Rio de Janeiro, Brazil.
  • Valério CM; Metabolism Unit, State Institute of Diabetes and Endocrinology, IEDE, Rio de Janeiro, Brazil.
  • Bragança JB; Metabolism Unit, State Institute of Diabetes and Endocrinology, IEDE, Rio de Janeiro, Brazil.
  • Oliveira Rde A; Metabolism Unit, State Institute of Diabetes and Endocrinology, IEDE, Rio de Janeiro, Brazil.
  • Zagury RL; Metabolism Unit, State Institute of Diabetes and Endocrinology, IEDE, Rio de Janeiro, Brazil.
  • Lustosa Rde P; National Cardiology Institute of Laranjeiras, Rio de Janeiro, Brazil.
  • Camargo GC; National Cardiology Institute of Laranjeiras, Rio de Janeiro, Brazil.
  • Nascimento CA; National Cardiology Institute of Laranjeiras, Rio de Janeiro, Brazil.
  • Moreira RO; Metabolism Unit, State Institute of Diabetes and Endocrinology, IEDE, Rio de Janeiro, Brazil.
Diabetol Metab Syndr ; 7: 29, 2015.
Article em En | MEDLINE | ID: mdl-25859279
ABSTRACT

BACKGROUND:

Dunnigan type Familial Partial Lipodystrophy (FPLD) is characterized by loss of subcutaneous fat from the limbs and excessive accumulation on the visceral adipose tissue (VAT). Affected individuals have insulin resistance (IR), diabetes, dyslipidemia and early cardiovascular (CV) events, due to their imbalanced distribution of total body fat (TBF). Epicardial adipose tissue (EAT) is correlated with VAT. Hence, EAT could be a new index of cardiac and visceral adiposity with great potential as a marker of CV risk in FPLD.

OBJECTIVE:

Compare EAT in FPLD patients versus healthy controls. Moreover, we aimed to verify if EFT is related to anthropometrical (ATPM) and Dual-Energy X-ray Absorptiometry (DEXA) measures, as well as laboratory blood findings. We postulated that FPLD patients have enlarged EAT.

METHODS:

This is an observational, cross-sectional study. Six patients with a confirmed mutation in the LMNA gene for FPLD were enrolled in the study. Six sex, age and BMI-matched healthy controls were also selected. EFT was measured by transthoracic echocardiography (ECHO). All participants had body fat distribution evaluated by ATPM and by DEXA measures. Fasting blood samples were obtained for biochemical profiles and also for leptin measurements.

RESULTS:

Median EFT was significantly higher in the FPLD group than in matched controls (6.0 ± 3.6 mm vs. 0.0 ± 2.04 mm; p = 0.0306). Additionally, FPLD patients had lower leptin values. There was no significant correlation between EAT and ATPM and DEXA measurements, nor laboratory findings.

CONCLUSIONS:

This study demonstrates, for the first time, that EAT measured by ECHO is increased in FPLD patients, compared to healthy controls. However, it failed to prove a significant relation neither between EAT and DEXA, ATPM or laboratory variables analyzed.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article